How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

    The content on this page is not current guidance and is only for the purposes of the consultation process.

    Interventional procedure overview of selective internal radiation therapy for neuroendocrine tumours that have metastasised to the liver

    Closed for comments This consultation ended on at   Request commenting lead permission

    Indications and current treatment

    NETs grow in many organs of the body. The tumours start in cells that release hormones into the bloodstream (neuroendocrine cells). The tumours commonly spread (mNETs) from other organs to the liver, where it may not be possible to remove them with surgery. Some mNETs produce hormones which can cause carcinoid syndrome. The main symptoms of carcinoid syndrome are flushing of the skin, diarrhoea, fast heart rate and breathlessness.

    Current treatment options depend on the history, clinical and histological presentation of mNETs. They include:

    • surgical resection

    • percutaneous ablation

    • systemic chemotherapy

    • systemic somatostatin analogues

    • PRRT

    • other intra-arterial therapies such as:

      • TAE

      • TACE

      • drug-eluting-bead-TACE.